What is the primary driver of the revenue increase in Q2 2008?

The primary driver of the revenue increase was a significant rise in contract research and development revenue from collaborations, particularly with sanofi-aventis (aflibercept and antibody programs) and Bayer HealthCare (VEGF Trap-Eye). Technology licensing revenue also contributed to the growth.

Why did Regeneron's net loss decrease despite higher expenses?

While research and development expenses increased substantially, the growth in revenues, especially from collaborations, outpaced the increase in operating expenses for the quarter. This led to a narrower net loss compared to the prior year period.

What is the status of ARCALYST (rilonacept) sales?

ARCALYST was launched commercially in March 2008 for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). While shipments to distributors totaled $1.6 million in Q2 2008, revenue recognition has been deferred due to no historical return or rebate experience. The company expects total shipments to distributors to reach approximately $10 million in 2008.

What significant financial maneuver did Regeneron undertake in Q2 2008?

Regeneron repurchased $81.3 million in principal amount of its 5.5% Convertible Senior Subordinated Notes due October 17, 2008, for $82.1 million. This proactive debt management reduced outstanding debt and associated interest.

REGN 10-Q Quarterly Report Q2 FY2008 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the period ending June 29, 2008. The company generated total revenues of $60.7 million for the second quarter of 2008, a significant increase from $22.2 million in the same period of 2007, primarily driven by substantial growth in contract research and development revenue from collaborations with sanofi-aventis and Bayer HealthCare, as well as technology licensing revenue. Despite increased revenues, Regeneron reported a net loss of $18.5 million ($0.23 per share) for the quarter, an improvement from a net loss of $26.8 million ($0.41 per share) in the prior year's second quarter. The company's research and development expenses also increased significantly to $66.6 million from $43.9 million, reflecting ongoing investments in its drug development pipeline, including ARCALYST, aflibercept, VEGF Trap-Eye, and new antibody programs. Financially, Regeneron maintained a solid liquidity position with $292.1 million in cash and cash equivalents and $408.3 million in marketable securities as of June 30, 2008. The company also successfully repurchased $81.3 million of its convertible debt in the second quarter, reducing its outstanding debt obligations.

Key Highlights

1Total revenues significantly increased to $60.7 million in Q2 2008 from $22.2 million in Q2 2007, largely due to higher collaboration revenues.
2Net loss narrowed to $18.5 million ($0.23/share) in Q2 2008 from $26.8 million ($0.41/share) in Q2 2007, indicating improved operational efficiency relative to revenue.
3Research and development expenses increased substantially to $66.6 million in Q2 2008, up from $43.9 million in Q2 2007, demonstrating continued investment in pipeline development.
4The company launched ARCALYST (rilonacept) commercially for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in March 2008.
5Cash and marketable securities remained robust, totaling $700.4 million as of June 30, 2008, providing ample liquidity.
6Regeneron repurchased $81.3 million of its 5.5% Convertible Senior Subordinated Notes in Q2 2008.
7Significant progress reported across late-stage clinical programs, including aflibercept for oncology and VEGF Trap-Eye for eye diseases.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2008

Summary

Key Highlights

Frequently Asked Questions